To contact Cabling Installation & Maintenance:

About Cabling Installation & Maintenance:

Bringing practical business and technical intelligence to today's structured cabling professionals.

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on:

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Segal Trials Plays Key Role in FDA Approval of COBENFY™, A New Era in Schizophrenia Treatment

Segal Trials is honored to have contributed significantly to the FDA approval of COBENFY™ (xanomeline and trospium chloride), a groundbreaking first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults. This approval marks a critical advancement in schizophrenia care, offering new hope to those living with the condition.

A Major Leap Forward in Schizophrenia Treatment

COBENFY™ provides a fresh approach to schizophrenia treatment by targeting muscarinic receptors, offering patients a reduction in symptoms of psychosis with fewer metabolic side effects than traditional antipsychotics. This novel pathway represents a major step forward in treatment options, improving both patient outcomes and quality of life​ (Patient Care Online)​(BMS News).

Segal Trials' Longstanding Involvement

Segal Trials has been involved with COBENFY™ from its early development under Karuna Therapeutics. Our partnership began during the initial phases of the EMERGENT program and continued after Bristol Myers Squibb acquired Karuna and brought COBENFY™ to market. Throughout this process, Segal Trials provided essential data across multiple phases, contributing to the pivotal clinical trials that led to FDA approval. This enduring partnership highlights Segal Trials' leadership in schizophrenia research, built on over 20 years of expertise.

A Transformative Moment for Mental Health Care

Dr. Rishi Kakar, Chief Scientific Officer at Segal Trials, remarked, “The FDA’s approval of COBENFY™ is a monumental step forward in schizophrenia treatment. We are proud to have contributed to this breakthrough, which will offer patients and clinicians a much-needed alternative in mental health care.”

Bonnie Segal, President of Segal Trials, added, “Our involvement with this groundbreaking treatment spans many years, from working with Karuna Therapeutics when the drug was originally known as KarXT, to continuing our partnership with Bristol Myers Squibb after the acquisition and rebranding of the drug as COBENFY™. This approval highlights the strength of longstanding collaborations in clinical research, and we are honored to have been part of bringing such an innovative treatment to patients."

Looking Ahead

As we celebrate this approval, Segal Trials is reminded of the immense potential that clinical research holds in improving patient outcomes. We remain committed to advancing treatments for mental health conditions through ongoing research and innovation.

For more information, visit: Segal Trials and the official Bristol Myers Squibb press release.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.